Sonoma Biotherapeutics Names Dr. Rajesh Krishnan as New CTO

Sonoma Biotherapeutics, a leading clinical-stage biotechnology company, has announced the appointment of Dr. Rajesh Krishnan as the new Chief Technical Officer. With over two decades of expertise in pharmaceutical product development and manufacturing, Dr. Krishnan is set to play a pivotal role in the company’s mission to advance therapies for autoimmune and inflammatory diseases. His extensive experience, particularly in cell therapy, is expected to bolster Sonoma’s efforts in developing innovative Treg therapies.

Sonoma Biotherapeutics, based in South San Francisco and Seattle, is dedicated to engineering regulatory T cell (Treg) therapies aimed at restoring immune system balance in patients with serious autoimmune conditions. Dr. Krishnan’s rich career includes significant roles at Oncternal Therapeutics, Dynavax Technologies, and Gilead Sciences, where he honed his skills in process development, technology transfer, and manufacturing sciences. His leadership at these companies has been marked by successful program development and a strong track record in transforming drug substance and product manufacturing practices.

Dr. Krishnan joins Sonoma Biotherapeutics at a crucial time as the company aims to advance its pipeline of potentially groundbreaking treatments. His presence is expected to strengthen the technical operations and leadership team, helping Sonoma bring its innovative Treg therapies to market. As Sonoma continues its pioneering work, Dr. Krishnan’s expertise will be invaluable in navigating the complex landscape of autoimmune disease treatment, promising exciting developments for the industry.

For the latest updates and in-depth insights into the world of Analytical Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!